RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)

• US 20060211642A1
• Filed: 12/19/2005
• Published: 09/21/2006
• Est. Priority Date: 05/18/2001
• Status: Abandoned Application

• Current Assignee: Sirna Therapeutics, Inc. (Alnylam Pharmaceuticals Incorporated)
• Original Assignee: Sirna Therapeutics, Inc. (Alnylam Pharmaceuticals Incorporated)
• Inventors: McSwiggen, James, Morrissey, David, Guerciolini, Roberto
• Application Number:
  US11/311,826
• Publication Number:
  US 20060211642A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2770/24211 Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Abstract

This invention relates to compounds, compositions, and methods useful for modulating Hepatitis C Virus (HCV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HCV gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HCV genes, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such such small nucleic acid molecules cocktails thereof. The application also relates to methods of treating diseases and conditions associated with HCV gene expression, such as HCV infection, hepatocellular carcinoma, cirrhosis, liver failure, as well as providing dosing regimens and treatment protocols.

Claims

1. A composition comprising a first double stranded nucleic and a second double stranded nucleic acid molecule each having a first strand and a second strand that are complementary to each other, wherein the second strand of said first double stranded nucleic acid molecule comprises sequence complementary to HCV sequence having SEQ ID NO:

1444 and the second strand of said second double stranded nucleic acid molecule comprises sequence complementary to HCV sequence having SEQ ID NO;

1417.

2. The composition of claim 1, further comprising a cationic lipid, a neutral lipid, and a polyethyleneglycol-conjugate.

3. The composition of claim 1, further comprising a cationic lipid, a neutral lipid, a polyethyleneglycol-conjugate, and a cholesterol.

4. The composition of claim 1, further comprising a cationic lipid, a neutral lipid, a polyethyleneglycol-conjugate, a cholesterol, and a surfactant.

5. The composition of claim 2, wherein said cationic lipid is selected from the group consisting of CLinDMA, pCLinDMA, eCLinDMA, DMOBA, and DMLBA.

6. The composition of claim 3, wherein said cationic lipid is selected from the group consisting of CLinDMA, pCLinDMA, eCLinDMA, DMOBA, and DMLBA.

7. The composition of claim 4, wherein said cationic lipid is selected from the group consisting of CLinDMA, pCLinDMA, eCLinDMA, DMOBA, and DMLBA.

8. The composition of claim 2, wherein said neutral lipid is selected from the group consisting of DSPC, DOBA, and cholesterol.

9. The composition of claim 3, wherein said neutral lipid is selected from the group consisting of DSPC, DOBA, and cholesterol.

10. The composition of claim 4, wherein said neutral lipid is selected from the group consisting of DSPC, DOBA, and cholesterol.

11. The composition of claim 2, wherein said polyethyleneglycol-conjugate is selected from the group consisting of a PEG-dimyristoyl glycerol and PEG-cholesterol.

12. The composition of claim 3, wherein said polyethyleneglycol-conjugate is selected from the group consisting of a PEG-dimyristoyl glycerol and PEG-cholesterol.

13. The composition of claim 4, wherein said polyethyleneglycol-conjugate is selected from the group consisting of a PEG-dimyristoyl glycerol and PEG-cholesterol.

14. The composition of claim 13, wherein said PEG is 2KPEG.

15. The composition of claim 4, wherein said surfactant is selected from the group consisting of palmityl alcohol, stearyl alcohol, oleyl alcohol and linoleyl alcohol.

16. The composition of claim 4, wherein said cationic lipid is CLinDMA, said neutral lipid is DSPC, said polyethylene glycol conjugate is 2KPEG-DMG, said cholesterol is cholesterol, and said surfactant is linoleyl alcohol.

17. The composition of claim 16, wherein said CLinDMA, said DSPC, said 2KPEG-DMG, said cholesterol, and said linoleyl alcohol are present in molar ratio of 43:

38;

10;

2;

7 respectively.

18. The composition of claim 1, wherein said first strand and said second strand of said first double stranded nucleic acid molecule comprise SEQ ID NOs:

1796 and 2010 respectively, and said first strand and said second strand of said second double stranded nucleic acid molecule comprise SEQ ID NOs;

1677 and 2011 respectively.

19. The composition of claim 1, wherein said first strand and said second strand of said first double stranded nucleic acid molecule comprise SEQ ID NOs:

1796 and 2012 respectively, and said first strand and said second strand of said second double stranded nucleic acid molecule comprise SEQ ID NOs;

1677 and 2013 respectively.

20. A composition comprising the composition of claim 1 in a pharmacuetically acceptable carrier or diluent.

21. A composition comprising the composition of claim 2 in a pharmacuetically acceptable carrier or diluent.

22. A composition comprising the composition of claim 3 in a pharmacuetically acceptable carrier or diluent.

23. A composition comprising the composition of claim 18 in a pharmacuetically acceptable carrier or diluent.

24. A composition comprising the composition of claim 19 in a pharmacuetically acceptable carrier or diluent.